Abingworth Management Ltd - Net Worth and Insider Trading
Abingworth Management Ltd Net Worth
The estimated net worth of Abingworth Management Ltd is at least $136 Million dollars as of 2024-11-07. Abingworth Management Ltd is the 10% Owner of Supernus Pharmaceuticals Inc and owns about 3,600,000 shares of Supernus Pharmaceuticals Inc (SUPN) stock worth over $136 Million. Abingworth Management Ltd is also the 10% Owner of Alnylam Pharmaceuticals Inc and owns about 395 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $107,835. Details can be seen in Abingworth Management Ltd's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Abingworth Management Ltd has not made any transactions after 2012-05-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Abingworth Management Ltd
Abingworth Management Ltd Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Abingworth Management Ltd owns 2 companies in total, including Supernus Pharmaceuticals Inc (SUPN) , and Alnylam Pharmaceuticals Inc (ALNY) .
Click here to see the complete history of Abingworth Management Ltd’s form 4 insider trades.
Insider Ownership Summary of Abingworth Management Ltd
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals Inc | 2012-05-04 | 10 percent owner |
| ALNY | Alnylam Pharmaceuticals Inc | 2005-01-05 | 10 percent owner |
Abingworth Management Ltd Latest Holdings Summary
Abingworth Management Ltd currently owns a total of 2 stocks. Among these stocks, Abingworth Management Ltd owns 3,600,000 shares of Supernus Pharmaceuticals Inc (SUPN) as of May 4, 2012, with a value of $136 Million and a weighting of 99.92%. Abingworth Management Ltd also owns 395 shares of Alnylam Pharmaceuticals Inc (ALNY) as of May 27, 2004, with a value of $107,835 and a weighting of 0.08%.
Latest Holdings of Abingworth Management Ltd
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SUPN | Supernus Pharmaceuticals Inc | 2012-05-04 | 3,600,000 | 37.75 | 135,900,000 |
| ALNY | Alnylam Pharmaceuticals Inc | 2004-05-27 | 395 | 273.00 | 107,835 |
Holding Weightings of Abingworth Management Ltd
Abingworth Management Ltd Form 4 Trading Tracker
According to the SEC Form 4 filings, Abingworth Management Ltd has made a total of 0 transactions in Supernus Pharmaceuticals Inc (SUPN) over the past 5 years. The most-recent trade in Supernus Pharmaceuticals Inc is the acquisition of 1,100,000 shares on May 4, 2012, which cost Abingworth Management Ltd around $6 Million.
According to the SEC Form 4 filings, Abingworth Management Ltd has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 0 shares on May 27, 2004, which brought Abingworth Management Ltd around $0.
Insider Trading History of Abingworth Management Ltd
- 1
Abingworth Management Ltd Trading Performance
GuruFocus tracks the stock performance after each of Abingworth Management Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Abingworth Management Ltd is 97.82%. GuruFocus also compares Abingworth Management Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Abingworth Management Ltd within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Abingworth Management Ltd's insider trading performs compared to the benchmark.
Performance of Abingworth Management Ltd
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -16.25 | | | | | |
| Relative Return to S&P 500(%) | -9.61 | | | | | |
Abingworth Management Ltd Ownership Network
Ownership Network List of Abingworth Management Ltd
Ownership Network Relation of Abingworth Management Ltd
Abingworth Management Ltd Owned Company Details
What does Supernus Pharmaceuticals Inc do?
Who are the key executives at Supernus Pharmaceuticals Inc?
Abingworth Management Ltd is the 10 percent owner of Supernus Pharmaceuticals Inc. Other key executives at Supernus Pharmaceuticals Inc include Sr. VP of IP & CSO Padmanabh P. Bhatt , Sr. V.P. & Regulatory Affairs Tami Tillotson Martin , and Sr VP & Quality & GMP Oper. & IT Frank Mottola .
Supernus Pharmaceuticals Inc (SUPN) Insider Trades Summary
Over the past 18 months, Abingworth Management Ltd made no insider transaction in Supernus Pharmaceuticals Inc (SUPN). Other recent insider transactions involving Supernus Pharmaceuticals Inc (SUPN) include a net sale of 98,505 shares made by Padmanabh P. Bhatt , a net sale of 21,235 shares made by Tami Tillotson Martin , and a net sale of 13,886 shares made by Georges Gemayel .
In summary, during the past 3 months, insiders sold 13,886 shares of Supernus Pharmaceuticals Inc (SUPN) in total and bought 0 shares, with a net sale of 13,886 shares. During the past 18 months, 146,329 shares of Supernus Pharmaceuticals Inc (SUPN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 146,329 shares.
Supernus Pharmaceuticals Inc (SUPN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Supernus Pharmaceuticals Inc Insider Transactions
Abingworth Management Ltd Mailing Address
Above is the net worth, insider trading, and ownership report for Abingworth Management Ltd. You might contact Abingworth Management Ltd via mailing address: 38 Jermyn Street, London X0 Sw1y 6dn.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
